Avinger Completes Enrollment in SCAN Clinical Study

Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has completed enrollment in the SCAN clinical study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries.

As quoted in the press release:

Enrollment in the SCAN study was initiated at two centers in the United States in June 2018 with the goal of acquiring at least 115 matched images generated by OCT and IVUS from up to 20 subjects diagnosed with PAD. The study exceeded this goal with greater than 115 OCT and IVUS matched images captured at identical positions within vessel segments from 14 subjects. These images have been submitted to three independent radiologists who will review the matched images and rank them for clarity to identify vessel morphology (e.g., the components of vessel wall layers, bifurcation) abnormal physiology (e.g., plaque, dissection, thrombus, calcium), and artifacts. Vessel measurement will also be compared between the two imaging modalities. Once final study results are available, it is anticipated that they will be publicly-released by Avinger and submitted for publication by the physician investigators in the study, Dr. Edward Pavillard, a vascular surgeon at PA Vascular Institute in King of Prussia, Pennsylvania, and Dr. Luke Sewall, an interventional radiologist and president of Vascular and Interventional Professionals in Hinsdale, Illinois.

“The SCAN study complements and expands the body of clinical data highlighting the importance of intravascular imaging for the diagnosis and treatment of peripheral arterial disease,” said Dr. Jaafer Golzar, Avinger’s chief medical officer. “Drs. Pavillard and Sewall have done a tremendous job enrolling in this important trial. Clinical experience has shown us that OCT is equivalent and in certain situations superior to IVUS for intravascular imaging. Once final results are available from SCAN, we hope to have a robust clinical study supporting this concept.”

Click here to read the full press release.